Endometrial safety and bleeding with HRT: What's new?

Climacteric

Volumn 10, Issue SUPPL. 2, 2007, Pages 66-70

  Sturdee, D W ^a  

^a SOLIHULL HOSPITAL   (United Kingdom)

Author keywords

Bleeding; Endometrium; Hormone replacement therapy; Postmenopause

Indexed keywords

CONJUGATED ESTROGEN; ESTRADIOL; ESTROGEN; GESTAGEN; LEVONORGESTREL; MEDROXYPROGESTERONE; NORETHISTERONE ACETATE; TIBOLONE;

ADULT; AGED; CANCER RISK; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED STUDY; DRUG SAFETY; ENDOMETRIUM; ENDOMETRIUM CANCER; FEMALE; HORMONE SUBSTITUTION; HUMAN; LOW DRUG DOSE; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; VAGINA BLEEDING;

ENDOMETRIAL HYPERPLASIA; ESTROGEN REPLACEMENT THERAPY; ESTROGENS, CONJUGATED (USP); EVIDENCE-BASED MEDICINE; FEMALE; HUMANS; NORPREGNENES; PROGESTERONE CONGENERS; UTERINE HEMORRHAGE; WOMEN'S HEALTH;

EID: 34548851996     PISSN: 13697137     EISSN: 14730804     Source Type: Journal    
DOI: 10.1080/13697130701546125     Document Type: Conference Paper

References (20)

1. Ferlay J, et al., GLOBOCAN 2002. Cancer Incidence, Mortality and Prevalence Worldwide. IARC Cancer Base No. 5, Version 2.0. Lyon: IARC Press, 2004
2. Ziel HK, Finkle WD. Increased risk of endometrial carcinoma among users of conjugated estrogens. N Engl J Med 1975;293:1167-70
3. Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women. JAMA 2002;288:321-33
4. Lethaby A, Suckling J, Barlow D, et al. Hormone replacement therapy in postmenopausal women: endometrial hyperplasia and irregular bleeding. Cochrane Database Syst Rev 2004;CD 000402
5. Anderson GL, Judd HL, Kaunitz AM, et al. The effects of progestogen plus progestin on gynaecologic cancers and associated diagnostic procedures: the Women's Health Initiative randomized trial. JAMA 2003;290:1739-48
6. Beral V, Bull D, Reeves G. Endometrial cancer and hormone replacement therapy in the Million Women Study. Lancet 2005;365:1543-51
7. Kloosterboer HJ. Tibolone: a steroid with a tissue-specific action. J Steroid Biochem Molec Biol 2001;76:231-8
8. Bruce D, Robinson J, Rymer J. Long-term effects of tibolone on the endometrium as assessed by bleeding episodes, transvaginal scan and endometrial biopsy. Climacteric 2004;7:261-6
9. Archer DF, Hendrix S, Gallagher JC, et al. Endometrial effects of tibolone. J Clin Endocrinol Metab 2007;92:991-8
10. Langer RD, Landgren B-M, Rymer J, Helmond FA: OPAL investigators. Effects of tibolone and continuous combined conjugated equine estrogen/ medroxyprogesterone acetate on the endometrium and vaginal bleeding: results of the OPAL study. Am J Obstet Gynecol 2006;195:1320-7
11. Archer DF, Pickar JH. The assessment of bleeding patterns in postmenopausal women during continuous combined hormone replacement therapy: a review of methodology and recommendations for reporting of the data. Climacteric 2002;5:45-59
12. Sturdee DW, Archer DF, Rakov V, Lang E. Low dose estradiol and norethindrone acetate: endometrial effects in postmenopausal women. Data presented at 11th IMS World Congress, Buenos Aires, October 2005
13. Hammar M, Christau S, Nathorst-Boos J, Rud T, Garre K. A double blind randomised trial comparing the effects of tibolone and continuous combined hormone replacement therapy in postmenopausal women with symptoms. Br J Obstet Gynaecol 1998;105:904-11
14. Panay N, Ylikorkala O, Archer DF, et al. Ultra-low dose estradiol and norethisterone acetate: effective menopause symptom relief. Climacteric 2007;10:120-31
15. Pickar JH, Yeh IT, Wheeler JE, Cunnane MF, Speroff L. Endometrial effects of lower doses of conjugated equine oestrogens and medroxyprogesterone acetate: two-year substudy results. Fertil Steril 2003;80:1234-40
16. Lundström E, Bygdeson M, Svane G, Azavedo E, von Schoultz B. Neutral effect of ultra-low-dose continuous combined estradiol and norethisterone acetate on mammographic breast density. Climacteric 2007;10:249-56
17. Johnson SR, Ettinger B, Macer JL, Ensrud KE, Quan J, Grady D. Uterine and vaginal effects of unopposed ultralow-dose transdermal estradiol. Obstet Gynecol 2005;105:779-87
18. Riphagen FE. Intrauterine application of progestins in hormone replacement therapy. Climacteric 2000;3:199-211
19. Hampton NR, Rees MC, Lowe DG, Rauramo I, Barlow DH, Guillebaud J. Levonorgestrel intrauterine system (LNG-IUS) with conjugated equine estrogens: a successful regimen for HRT in perimenopausal women. Hum Reprod 2005;20:2653-60
20. Cicinelli E, de Ziegler D, Alfonso R, et al. Endometrial effects, bleeding control, and compliance with a new postmenopausal hormone therapy regimen based on transdermal estradiol gel and every-other-day vaginal progesterone in capsules: a 3-year pilot study. Fertil Steril 2005;83:1859-63